Evotec SE: Positive Phase IIb Data for Investigational P2X3 Antagonist in Patients with Refractory Chronic Cough

·1 min read

HAMBURG, GERMANY / ACCESSWIRE / August 3, 2021 / Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480) announces that the Company has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough. The underlying molecule is a P2X3 receptor antagonist in Bayer's clinical development pipeline originating from a former Evotec/Bayer multi-target research alliance. The primary efficacy outcome was met showing a statistically significant improvement in 24-hour cough counts per hour (average hourly cough frequency based on 24-hour sound recordings) over placebo after 12 weeks of treatment. The data showed a favourable safety and tolerability profile.

Under the agreement from 2012, Evotec would be entitled to its next financial milestone payment upon start of a Phase III clinical study, to be decided by Bayer.

More details of the study will be presented by Bayer.


Dr Werner Lanthaler
Chief Executive Officer
Evotec SE
Manfred Eigen Campus
Essener Bogen 7, 22419
Hamburg, Germany
Phone: +49.(0)40.560 81-242


View source version on accesswire.com:

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting